托利咪酮
![]() | |
臨床資料 | |
---|---|
其他名稱 | CP-26154, MLR-1023 |
識別資訊 | |
| |
CAS號 | 41964-07-2 |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.230.742 |
化學資訊 | |
化學式 | C11H10N2O2 |
摩爾質量 | 202.21 g·mol−1 |
3D模型(JSmol) | |
|
托利咪酮(英語:Tolimidone,開發代號:CP-26154、MLR-1023)是一種有機化合物,分子式C11H10N2O2,由輝瑞公司的科學家研發,可刺激胃黏膜分泌,輝瑞公司曾計劃將其開發為胃及十二指腸潰瘍藥物,但因種種原因失敗[1][2][3]。
參考文獻
- ^ Tolimidone. AdisInsight. [26 August 2017]. (原始內容存檔於2023-07-27) (英語).
- ^ Lipinski, C. A.; Stam, J. G.; Pereira, J. N.; Ackerman, N. R.; Hess, H. J. Bronchodilator and antiulcer phenoxypyrimidinones. Journal of Medicinal Chemistry. 1980, 23 (9): 1026–31. PMID 7411545. doi:10.1021/jm00183a012.
Compound 3 has been assigned the nonproprietary (USAN) name tolimidone
- ^ Lipinski CA, Reaume AG. High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. Bioorg Med Chem. May 2020, 28 (8): 115425. PMID 32201192. doi:10.1016/j.bmc.2020.115425
.